ReviewJournal of integrative medicine2014
Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities.
Review in Journal of integrative medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Fuzheng Huayu preparation (/) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Pooled it
- Adjuvant effect of herbal medicine on transarterial chemoembolization in patients with hepatocellular carcinoma: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Yangyin Fuzheng Jiedu prescription as an adjunct to minimally invasive treatment in early-stage hepatocellular carcinoma: a randomized controlled trial.Frontiers in pharmacology · 2026Trial
- Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).Phytomedicine : international journal of phytotherapy and phytopharmacology · 2021Trial
- Liver Disease and Plant-Derived Phytoconstituents: From Ethnopharmacology to Modern Medicine.Phytotherapy research : PTR · 2026Review
- Accurate fatty liver disease diagnosis with a multi-source feature fusion model on the segmented tongue image dataset.Journal of advanced research · 2026Article
- Multi-target modulation of traditional Chinese medicine based on the liver-gut axis: a new therapeutic strategy for NAFLD.American journal of translational research · 2026Review
- Article
- Phytochemical screening, antioxidant, and antimicrobial analysis of Portulaca oleracea seeds with in-silico molecular docking insights.Journal, genetic engineering & biotechnology · 2025Article
- Resilience of Portulaca plants to environmental stresses and the economic potential of their bioactive compounds.Planta · 2025Review
- Traditional Chinese Medicine as a Tool for the Treatment of Hepatocellular Carcinoma by Targeting Pathophysiological Mechanism.Cancer management and research · 2025Review
- Banxia Xiexin Tang attenuates high glucose-induced hepatocyte injury by activating SOD2 to scavenge ROS via PGC-1α/IGFBP1.3 Biotech · 2024Article
- Article
- Twelve Shugan Lidan Granules from traditional Chinese medicine can improve liver function in patients with postoperative hepatolithiasis by inhibiting the Hippo signaling pathway.American journal of translational research · 2024Article
- Article
- Alisma Shugan Decoction attenuates hepatic fibrosis and endoplasmic reticulum stress in mice with carbon tetrachloride-induced fibrosis.African health sciences · 2023Article
- Systematic analysis of randomised controlled trials of Chinese herb medicine for non-alcoholic steatohepatitis (NASH): implications for future drug development and trial design.Chinese medicine · 2023Review
- Phytochemical Characteristics and Anti-Inflammatory, Immunoregulatory, and Antioxidant Effects ofEvidence-based complementary and alternative medicine : eCAM · 2023Review
- Sodium New Houttuyfonate Inhibits Cancer-PromotingCancers · 2022Article
- Chinese medicine in the treatment of autoimmune hepatitis: Progress and future opportunities.Animal models and experimental medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional Chinese medicine (TCM) is commonly used in treating liver diseases worldwide, especially in China. The advantages of using TCM for treatment of liver diseases include: protecting hepatocytes, inhibiting hepatic inflammation and antifibrosis in the liver. In this article, we introduce TCM herbal preparations from the Chinese materia medica (such as Fuzheng Huayu) that are typically used for the treatment of liver diseases. Literature surrounding the mechanisms of TCM therapy for treatment of liver diseases is presented and discussed. We propose that side effects of herbal compounds are often under-appreciated, and that more care should be taken in the prescription of potentially hepatotoxic medicines. Further, to deepen the understanding of TCM mechanisms, new techniques and methodologies must be developed. Future studies will lead to the enhancement of clinical outcomes of TCM. As complementary and alternative therapies, TCMs will play an expanding role in the future of liver disease treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.